Story Summary: These data, along with the publication last week of a report showing that therapeutic miRNA delivery could suppress tumorigenesis in a mouse model of liver cancer, suggest that miRNA replacement could be a safe and effective therapeutic strategy for cancer, Mirna CEO Matt Winkler told RNAi Newsthis week. As such, Mirna expects to begin clinical testing of its first drug candidate by 2011, he said. Winkler attributed miR-Rx34s apparent safety to a combination of the drugs potency and the fact that miRNAs are a natural part of human biology. Selection of a lead candidate, he added, will be driven by data from work leading up to an investigational new drug application. Mirna has publicly disclosed three oncology indications non-small cell lung cancer, metastatic prostate cancer, and acute myeloid leukemia as its areas of interest. In addition, the company has investigated the possibility of using miRNA-replacement therapy to sensitize cancer cells to conventional chemotherapeutics (see RNAi News, 6/19/2008). She takes a three-pronged approach to stimulate the body to regenerate beta cells. To this end, her lab develops cell-based assays to observe different aspects of beta cell function and health, and then performs screens with small organic synthetic compounds. BlogPapers of NoteAn Integrated Genetic and Cytogenetic Map of the Cucumber GenomeRen Y, Zhang Z, Liu J, Staub JE, Han Y, et al. In a paper appearing online last week in PLoS ONE, researchers from the Chinese Academy of Agricultural Sciences, the China Agricultural University, and the US Department of Agricultures Agricultural Research Service used whole genome shotgun sequencing to come up with nearly 1,000 polymorphic simple sequence repeat markers in cucumber. Using these markers, along with cytogenetic data, they then created a high-density linkage map thats expected to form the foundation for future genetic and genomic studies in cucumbers and related plants. Using these markers, along with cytogenetic data, they then created a high-density linkage map thats expected to form the foundation for future genetic and genomic studies in cucumbers and related plants. Epigenetic Temporal Control of Mouse Hox Genes in VivoSoshnikova and Duboule, ScienceIn this weeks issue of Science, Swiss scientists checked into how the Hoxgenes might be regulated by epigenetics. The results, they say, suggest that chromatin modifications are important parameters in the temporal regulation of this gene family, and moreover, that the so-called Hoxclock could be controlled by epigenetics. The results, they say, suggest that chromatin modifications are important parameters in the temporal regulation of this gene family, and moreover, that the so-called Hoxclock could be controlled by epigenetics. People on the MoveCompugensaid this week that Anat Cohen-Dayag and Martin Gerstelwill serve as co-CEOs of the company. Cohen-Dayag started with the company in 2002, and she has served as VP for diagnostic biomarkers and drug targets. Before starting at Compugen, she was head of RD at Mindsense Biosystems. Before starting at Compugen, she was head of RD at Mindsense Biosystems.

Similar posts: colorectal cancer

We're sorry, but we could not fulfill your request for / on this server.
An invalid request was received. You claimed to be a major search engine, but you do not appear to actually be a major search engine.
Your technical support key is: c1c8-ad99-f118-2195
You can use this key to fix this problem yourself.
If you are unable to fix the problem yourself, please contact judi.sohn at fightcolorectalcancer.org and be sure to provide the technical support key shown above.

Similar posts: colorectal cancer

There are many useful changes one can make and they are removing the known causes and with the amazing self-healing powers of our immune system, which we were born with and are with us right through life, the body can heal and we can become cancer free.
All cancers including colon cancer have 4 main causes and they are our wrong food choices, the toxic chemicals we encounter everyday, our sedentary lifestyle or our lack of exercise and lastly emotional stress or not letting go of a problem we may have. Let’s look at each one of these.

Similar posts: colorectal cancer

We're sorry, but we could not fulfill your request for / on this server.
An invalid request was received from your browser. This may be caused by a malfunctioning proxy server or browser privacy software.
Your technical support key is: c1c8-ad99-1756-6707
You can use this key to fix this problem yourself.
If you are unable to fix the problem yourself, please contact judi.sohn at fightcolorectalcancer.org and be sure to provide the technical support key shown above.

Similar posts: colorectal cancer

We're sorry, but we could not fulfill your request for / on this server.
An invalid request was received. You claimed to be a major search engine, but you do not appear to actually be a major search engine.
Your technical support key is: c1c8-ad99-e4de-0453
You can use this key to fix this problem yourself.
If you are unable to fix the problem yourself, please contact judi.sohn at fightcolorectalcancer.org and be sure to provide the technical support key shown above.

Similar posts: colorectal cancer

11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles about his data on the relevance of KRAS tumor status to the choice of molecular therapy for patients with metastatic colorectal cancer. Whether the gene is wild-type or mutant determines sensitivity of the tumor to anti-epidermal growth factor or anti-vascular endothelial growth factor receptor therapy. Dr Macdonald also discusses the disappointing finding that blocking both of these proliferation pathways does not lead to improved efficacy when two targeted drugs are used in combination.

Similar posts: colorectal cancer

In response to the rapid pace of technological development in the field of intracranial endovascular cerebrovascular interventions, the American Heart Association has released guidelines on performance of such procedures to treat a range of cerebrovascular disorders. The indications were laid out in a statement published online April 6 in Circulation: Journal of the American Heart Association.

Similar posts: colorectal cancer

We're sorry, but we could not fulfill your request for / on this server.
An invalid request was received. You claimed to be a major search engine, but you do not appear to actually be a major search engine.
Your technical support key is: c1c8-ad99-f118-2195
You can use this key to fix this problem yourself.
If you are unable to fix the problem yourself, please contact judi.sohn at fightcolorectalcancer.org and be sure to provide the technical support key shown above.

Similar posts: colorectal cancer

Boston: March 26th and 27th, 2009*
Charles River Public Internet Center- 154 Moody St. Waltham, MA, 02454
*Note: These are one day workshops (8:30am - 4:30pm). Participants choose which one day to attend.

More Info/Registration: http://www.urban-research.info/workshops/massachusetts-gis.htm

Audience: Beginners, anyone interested in mapping their community

Participants will learn to use ArcGIS 9.3 to do the following:

Create thematic maps
Participants will learn to create thematic maps of their own data, and display spatial trends in information.

Address mapping (geocoding)
Participants will learn to map addresses of their clients, their projects or incidents such as crime and disease.

Download and Map Census American Community Survey Data
Participants will learn to extract and map current Census data such as poverty, race, language, population, transportation, education and workforce characteristics.

Participants will also learn to:
Conduct spatial queries
Download free shapefiles
Create well-designed maps

Mapping techniques transferable to all other communities. Exercises are designed for beginners. Intermediate Excel skills required.

Materials
+ Comprehensive workbook (75 pages), which includes the presentation, exercises and reference worksheets,

+ ArcGIS (ArcView 9.3) software 60-day trial CD set,

+ Thirty day free access to new 2005 Tiger/Line geography files (converted to shapefiles) which include streets, zip codes, school districts, voting districts, census tracts and many other useful geographies

+ Thirty day free access to our Analyzing Your Community: Local Demographic Analysis Online Workshop



Praise for the Introduction to GIS Community Analysis Workshop

Upton Massachusetts AIDS Action Committee: Very interesting course and a great introduction.

Boston Private Industry Council: Very useful - practical exercises that introduced me to the features and tools of ArcGIS and its potential for displaying information.

University of Massachusetts Medical School: This was a great intro to GIS. I feel like I can start to incorporate GIS into work projects.

City of Boston: I attained a good overview ArcGIS, and a basic understanding of shape files, joins, queries.



New Urban Research, Inc. is a national social research organization specializing in quantitative and spatial community analysis. NUR is an ESRI Business Partner. New Urban Research, Inc. 2301 NW Thurman Street, Portland, Oregon 97210 | 877.241.6576 | www.newurbanresearch.

Similar posts: colorectal cancer

Boston: March 26th and 27th, 2009*
Charles River Public Internet Center- 154 Moody St. Waltham, MA, 02454
*Note: These are one day workshops (8:30am - 4:30pm). Participants choose which one day to attend.

More Info/Registration: http://www.urban-research.info/workshops/massachusetts-gis.htm

Audience: Beginners, anyone interested in mapping their community

Participants will learn to use ArcGIS 9.3 to do the following:

Create thematic maps
Participants will learn to create thematic maps of their own data, and display spatial trends in information.

Address mapping (geocoding)
Participants will learn to map addresses of their clients, their projects or incidents such as crime and disease.

Download and Map Census American Community Survey Data
Participants will learn to extract and map current Census data such as poverty, race, language, population, transportation, education and workforce characteristics.

Participants will also learn to:
Conduct spatial queries
Download free shapefiles
Create well-designed maps

Mapping techniques transferable to all other communities. Exercises are designed for beginners. Intermediate Excel skills required.

Materials
+ Comprehensive workbook (75 pages), which includes the presentation, exercises and reference worksheets,

+ ArcGIS (ArcView 9.3) software 60-day trial CD set,

+ Thirty day free access to new 2005 Tiger/Line geography files (converted to shapefiles) which include streets, zip codes, school districts, voting districts, census tracts and many other useful geographies

+ Thirty day free access to our Analyzing Your Community: Local Demographic Analysis Online Workshop



Praise for the Introduction to GIS Community Analysis Workshop

Upton Massachusetts AIDS Action Committee: Very interesting course and a great introduction.

Boston Private Industry Council: Very useful - practical exercises that introduced me to the features and tools of ArcGIS and its potential for displaying information.

University of Massachusetts Medical School: This was a great intro to GIS. I feel like I can start to incorporate GIS into work projects.

City of Boston: I attained a good overview ArcGIS, and a basic understanding of shape files, joins, queries.



New Urban Research, Inc. is a national social research organization specializing in quantitative and spatial community analysis. NUR is an ESRI Business Partner. New Urban Research, Inc. 2301 NW Thurman Street, Portland, Oregon 97210 | 877.241.6576 | www.newurbanresearch.

Similar posts: colorectal cancer

GREGORY P. KALEMKERIAN, MD
Co-Director, Thoracic Oncology
Professor of Medicine
University of Michigan
Ann Arbor, Michigan

Financial Disclosure:
Dr. Kalemkerian is a member of the speakers bureau for Genentech and Lily and is a consultant for Merck and ImClone. He has also received research support from Pfizer, Abbott, Lilly, and Genentech.

Small-cell lung cancer (SCLC) is a distinct clinicopathologic entity that is characterized by neuroendocrine differentiation, early metastatic spread, and initial responsiveness to cytotoxic therapy. Despite appropriate therapy, most patients eventually relapse and die of chemoresistant disease, resulting in an overall 5-year survival rate of only 5%. Although the incidence of SCLC appears to be declining in the United States, it still accounts for 15% to 20% of all cases of lung cancer and 25,000 to 30,000 deaths per year.[1]

Historical Background

Twenty-five years ago, oncologists were optimistic that SCLC would soon be routinely cured with chemotherapy.[2] Cisplatin-based regimens had just tamed testicular cancer, and the dramatic responses reported in patients with SCLC suggested that a cure for this disease was just around the corner. However, we learned that responseseven complete responsesdo not necessarily translate into cures, and the overall survival of patients with SCLC has changed little in the past 2 decades.[3,4]

Historically, patients with SCLC who did not receive therapy had a very poor prognosis, with a median survival of 7 weeks for those with extensive-stage disease (ES) and 14 weeks for limited-stage disease (LS).[5] Over the years, many therapeutic strategies have been evaluated in an attempt to improve the outcome of patients with SCLC. Some of these approaches have succeeded in prolonging survival (Table 1), while many others have proven to be ineffective despite promising preclinical or early clinical findings (Table 2). With modern therapy, we can now expect a median survival of 9 to 10 months in patients with ES SCLC and 18 to 24 months in those with LS SCLC. Most importantly, long-term survival is now possible in 20% to 25% of patients with LS SCLC.

In this issue of ONCOLOGY, Hann and Rudin present a concise and practical overview of the management of SCLC that is consistent with the current National Comprehensive Cancer Network (NCCN) guidelines.[6] They accurately summarize the historical development of therapy for SCLC and present data from clinical studies that support current therapeutic recommendations. Since there is little to disagree with in their review, the remainder of this commentary will focus on some controversial advances that have not been widely incorporated into standard care.

Radiotherapy

Since SCLC is primarily considered a systemic disease, with over two-thirds of patients presenting with hematogenous metastases, it is somewhat surprising that recent progress has mainly involved the use of radiotherapy. From the standpoint of absolute survival, the greatest potential gain was noted in the study by Turrisi et al, in which patients with LS SCLC receiving early, concurrent hyperfractionated thoracic radiotherapy plus EP (etoposide plus cisplatin [Platinol]) were found to have a 10% improvement in long-term survival over those receiving once-daily radiation plus EP.[7] Although this study has been criticized for the relatively low biologic equivalent dose given in the once-daily radiation arm, the results achieved with hyperfractionated radiation are the best reported to date in patients with LS SCLC. Clearly, the acute toxicity of hyperfractionated radiation may be prohibitive in patients with poor performance status or large treatment fields. However, this approach remains underutilized even in those without contraindications, and more effort needs to be made to incorporate hyperfractionated radiotherapy into the care of our patients.

Prophylactic cranial irradiation (PCI) is another radiotherapy approach that has been shown to improve survival in patients with both LS and ES SCLC. In LS SCLC, PCI can improve long-term survival by 5.4%, suggesting that some patients were destined to relapse only in the brain.[8] As expected, the benefit of PCI in patients with ES SCLC is more limited (since they will ultimately relapse at other sites), and PCI may not be appropriate for all patients, particularly the elderly and those with preexisting neurologic or cognitive deficits. Nevertheless, the 14% improvement in 1-year survival after PCI noted in the recent European Organisation for Research and Treatment of Cancer (EORTC) trial represents a significant advance in ES SCLC.[9] Interestingly, many oncologists have not embraced the use of PCI in this setting, whereas they have overwhelmingly incorporated bevacizumab (Avastin) into the treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) despite a 1year survival benefit of only 7%, half of that seen with PCI.

Chemotherapy

Platinum-based chemotherapy is the standard in both SCLC and NSCLC, but the issue of cisplatin vs carboplatin remains a point of controversy. In advanced NSCLC, meta-analyses have demonstrated a small, statistically significant, but clinically meaningless benefit for cisplatin.[10,11] Data directly comparing cisplatin- to carboplatin-based regimens in SCLC are sparse. A small, randomized trial of cisplatin plus etoposide vs carboplatin plus etoposide in patients with LS or ES SCLC revealed no differences in response or survival, but less toxicity with carboplatin.[12] Informal comparison of response rates and survival data from phase II and III trials using either cisplatin- or carboplatin-based regimens suggests similar outcomes with either drug in both LS and ES SCLC.

Therefore, in light of the palliative nature of therapy in ES SCLC and the increased nonhematologic toxicity of cisplatin, it seems prudent to favor carboplatin-based therapy for patients with ES SCLC. In LS SCLCa curable disease for which there is less data on the equivalence of carboplatinit is reasonable to favor cisplatin-based therapy, with use of carboplatin reserved for those in whom cisplatin is contraindicated or poorly tolerated.

Despite the availability of numerous chemotherapeutic agents with activity against SCLC (Table 3), it is unlikely that empiric regimens of traditional cytotoxic drugs will lead to dramatic improvements in survival. Over the past 2 decades, our understanding of the molecular events that mediate the development and progression of SCLC has expanded dramatically. The identification of numerous molecular targets in SCLC cells has spawned a wide variety of novel therapeutic strategies.[13] Thus far, none of these approaches has demonstrated substantial clinical activity (Table 2). However, SCLC is a molecularly heterogeneous disease, so we must continue to refine emerging strategies in the laboratory and efficiently evaluate them in the clinic in an effort to identify patients who will benefit most from any specifically targeted approach.




1. Navada S, Lai P, Schwartz AG, Kalemkerian GP: Temporal trends in small cell lung cancer: Analysis of the national Surveillance, Epidemiology, and End Results database (abstract 7082). J Clin Oncol 24(18S):384s, 2006.

2. Aisner J, Alberto P, Bitran J, et al: Role of chemotherapy in small cell lung cancer: A consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep 67:37-43, 1983.

3. Lassen UN, Hirsh FR, Osterlind K, et al: Outcome of combination chemotherapy in extensive stage small-cell lung cancer: Any treatment related progress? Lung Cancer 20:151-160, 1998.

4. Chute JP, Chen T, Feigal E, et al: Twenty years of phase II trials for patients with extensive-stage small-cell lung cancer: Perceptible progress. J Clin Oncol 17:1794-1801, 1999.

5. Greco FA, Oldham RK: Clinical management of patients with small cell lung cancer, in Greco FA, Oldham RK, Bunn PA (eds): Small Cell Lung Cancer, pp 353-379. New York, Grun Stratton, 1981.

6. Kalemkerian GP, Akerley W, Downey RJ, et al: Small cell lung cancer. J Natl Compr Canc Netw 6:294-314, 2008. 7. Turrisi AT, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999.

8. Auperin A, Arriagada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 341:476-484, 1999.

9. Slotman B, Faivre-Finn C, Kramer G, et al: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664-672, 2007.

10. Ardizzoni A, Boni L, Tiseo M, et al: Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 99:847-857, 2007.

11. Hotta K, Matsuo K, Ueoka H, et al: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852-3859, 2004.

12. Sklaros DV, Samantas E, Kosmidis P, et al: Randomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 5:601-607, 1994.

13. Worden FP, Kalemkerian GP: Therapeutic advances in small cell lung cancer. Expert Opin Invest Drugs 9:565-579, 2000.


Article Tools
Email icon Send as email Print this page
Peerclip icon Discuss this article on Peerclip
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals
CME on Lung Cancer
Evidence on Lung Cancer
Guidelines on Lung Cancer
Patient Education on Lung Cancer
Clinical Trials on Lung Cancer
Practical Articles on Lung Cancer
Research and Reviews on Lung Cancer
All "Lung Cancer" results


Click here to find out more!

Click here.

Similar posts: colorectal cancer

We're sorry, but we could not fulfill your request for / on this server.
An invalid request was received from your browser. This may be caused by a malfunctioning proxy server or browser privacy software.
Your technical support key is: c1c8-ad99-1756-6707
You can use this key to fix this problem yourself.
If you are unable to fix the problem yourself, please contact judi.sohn at fightcolorectalcancer.org and be sure to provide the technical support key shown above.

Similar posts: colorectal cancer

-We made a poster for our third grade book buddies (who come down and read with out kids once a week) to tell them good luck on the TAKS test next week. The poster said "Hands Down, you guys are the best! Rock the TAKS!" so I had the kids come one at a time into the hall and I painted their hand and they got to leave their handprint and write their name on the poster. One little "Tony" (he loves skateboarding, so I will just call him Tony, as in Tony Hawk) who is in trouble most of the time (he is the male version of Montana, in a way) totally opened up to me. It was quiet just for a second while I was painting his hand and he blurted out "my mom just got out of rehab!" I didn't really know what to say, or what I was allowed to say, but I could tell he was proud and wanted to talk about it, so I just said "is she doing good?" and he said "yeah, she even got a job. I'm glad she is back home." and then he changed the subject to power rangers. I have to admit I totally tuned out as he recounted his favorite episode of Power Rangers. I was just thinking to myself "no five year old should know what rehab is....no wonder he can't behave at school...he has a crazy homelife!" It is sad, but I am glad that things seem to be on a good path for now. I hope they stay that way.
-the kids studied Honest Abe Lincoln last week and this week they are learning about George Washington. We made little stand up George Washington's in class, and the kids were supposed to write thier names on the back. I was going around checking to make sure they have written thier names, when I got to Montana's and had to stop. She had scribbled "B O M" on the back of George's head. I said "that doesn't look like your name! What does that say?" and very proud of herself she said "that spells BOMB!" I said "why would you write that?" and she said "because I want to kill him, because I hate him!" I said, why do you hate him? and she explained to me that her big brother (who is 14) "Hates George, because he like Barack Obama!" Inside it clicked that she was confusing George W. Bush (who I am assuming her great role model of a big brother dislikes) and George Washington. Needless to say, we had a long chat about how we don't talk about bombs and killing people, and especially not at school. Sigh...she is SIX years old, and already doesn't have the same chances to succeed in life as some of her classmates. It is so sad to me that home life pretty much defines a kid at this age.
-Fire drill today, but of course I was in the office making copies, so I had NO clue what to do. Some poor little first grader was walking the lunch count down to the cafeteria, so he was in the hall by himself scared, so we walked outside together. I didn't know that he was lost and a mad search was going on for him indoors, but I finally found someone with a walkie-talkie and they paged the "sweepers" in the building that he was safe and outside. Phew!
I found out from my University Supervisor that I will be getting observed on March 11th! I looked on a calendar and I only have four more days with my kinder kids! :( After spring break, I switch to 2nd grade, which I am not sure if I will like or not. I know I will miss all my little Kinder Cubs.

Similar posts: colorectal cancer

We're sorry, but we could not fulfill your request for / on this server.
An invalid request was received from your browser. This may be caused by a malfunctioning proxy server or browser privacy software.
Your technical support key is: c1c8-ad99-1756-6707
You can use this key to fix this problem yourself.
If you are unable to fix the problem yourself, please contact judi.sohn at fightcolorectalcancer.org and be sure to provide the technical support key shown above.

Similar posts: colorectal cancer

We're sorry, but we could not fulfill your request for / on this server.
An invalid request was received from your browser. This may be caused by a malfunctioning proxy server or browser privacy software.
Your technical support key is: c1c8-ad99-1756-6707
You can use this key to fix this problem yourself.
If you are unable to fix the problem yourself, please contact judi.sohn at fightcolorectalcancer.org and be sure to provide the technical support key shown above.

Similar posts: colorectal cancer

Wine, along with food, is one of the pleasures of the table. Jean-Louis Photoarchive PradelsV Did we put the dry bread and water? After calls for a boycott against the foie gras, Roquefort overtaxation the United States, the wine drink.
Bachelot law, under discussion next week before the National Assembly, causing anger among the winemakers.
In Bordeaux, professionals brandish the threat of a general mobilization. They are supported by parliamentarians girondins including UMP deputies. Around Toulouse and Montpellier, this ferment around the winery.
In question: Bill Hospital, patients, health and Territories (HPST) by Health Minister Roselyne Bachelot. A component of this law on the fight against alcoholism. Article 24 states the prohibition to provide free alcoholic beverages for promotional purposes, or to sell the package.
This bill seeks to prohibit the evening open bar of youth. The Health Minister has assured that the ban on selling alcohol package would not prevent tastings at fairs or in the wine cellars. But professionals are not reassured.
For in addition to this Article 24, the amended draft restricts the use of internet for the promotion of alcohol: We could no longer mention the wine on the sights, the press, the tenants are concerned.
To support his bill, the Minister of Health has rightly referred to a study by the National Cancer Institute, the Inca, that the risk of disease increases from the first glass. This study goes against many others on the benefits of moderate wine consumption: protection against cardiovascular disease, Alzheimer
Between cancer and Alzheimers, what should we choose?
It would kill the wine industry than would otherwise be the prohibition of wine tastings and communication on the Internet, said Laurent Gapenne late Friday, President of the Federation des grands vins de Bordeaux.
According Credoc, France lost its position as the worlds largest producer of wine in 2015 in favor of Spain. Consumption is falling in our country, the wine culture is lost among consumers. Bachelot and the law that pushes the cap
The boycott of Roquefort is too strong Rémi Pech: Wine is a convivial
Remi Pech is a historian, honorary president of the University of Toulouse-Le Mirail. He led with Christian teaching Béringuier wine.
DEPECHE OF THE SUNDAY: The vine is not rooted in our culture?
Remi PECH: Wine is a symbol that is found in the Christian religion, with the Eucharist, Jewish. They even praise of wine at major Muslim authors, like Omar Kayyam. The wine is part of the religious heritage is a part of the liturgy. And this culture has spread into civil society. A wine-friendliness: all meetings, meals go for a drink. The wine is not an ordinary drink.
GOLD: What do you think of the recent study by the Institute of Cancer?
R. P. If it is on the scientific and medical field, we must put everything on the table. A few years ago, an American study has shown that moderate consumption of red wine protects the risk of cardiovascular disease. We forget today.
GOLD: Do you think the bill to remove the tasting is to reduce alcohol abuse?
R. P. This would be a serious problem for winemakers, tasters, against-productive. One can observe that consumption of wine has been divided by two, and that alcohol does not backwards. Other alcoholic products, beer, spirits, do not the same attacks.
I think our society manifests a certain masochism. In times of crisis, there is a reluctance towards the pleasures of life, like wine.
Europe does not eat American beef with hormones? The United States decide, as a retaliatory measure, charging 300% Roquefort as of March 23. Certainly, Americans do not tartinent cheese-burger cheese made from ewes milk.
But the annual sales of Roquefort, the USA, are not 450 tons, or 2% of sales producers Aveyron. What do cheese.
SA cellars of Roquefort, with 1400 jobs, is one of the largest in the region Midi-Pyrenees.
When associations will take force-feeding geese and ducks Sure. Menus for Christmas Eve, the neck is twisted a few ducks. The foie gras dish is the feast of the French in 2007, they have spent an average of 28 to 30 € for their purchases of foie gras.
But a movement born in the United States wants to ban the force-feeding of geese and ducks. The protectors of animals denounce a practice involving the cruel suffering and death of millions of animals each year. In some U.S. cities, restaurants no longer have to include foie gras on their menu.
France is the leading producer in the world with 21,000 tonnes in 2008, our country is also the first consumer of foie gras.
Production is concentrated in the Southwest, the Landes and Gers particular. But in France too, animal protection associations want to ban the feeding and called for Europe.
Jean-Michel Baylet, Senator, Chairman of Tarn-et-Garonne: We will fight against this bill on the hospital that blends genres and brought the wine for a shameful disease.
Of course, excess is always harmful. But wine is one of our most noble traditions, it is a treasure of our heritage. Not to forget that wine is a considerable sector of our economy that supports thousands of families, especially in rural areas.
Michèle Delaunay, MP de Gironde: Some studies on the effects of wine consumption are presented in a biased and incomplete.
We must not forget that this is the lifestyle that goes with moderate consumption of wine that makes the quality of the meal. Some studies show that if you drink two glasses of wine a day lowers risk of Alzheimers disease.
Martin Malvy, President of Conseil Régional Midi-Pyrenees: Regarding the taxation of Roquefort, he wrote to U.S. President Barack Obama to protest.
I consider that the action taken by the United States is unjust. Roquefort cheese has become hostage involuntary international agreements on imports and exports of agricultural products.

Similar posts: colorectal cancer

Pharma Executive. Taken as a group, I realised that things have changed a lot in the last few years in terms of digital media and PR, although few are really exploiting the arena. Things are still evolving in the Pharma industry as a few players have only just started to experiment with the cool social media tools that are out there. There will be a lot of interesting battles with internal medical-legal-regulatory review teams to come though.
Back in 2000, when I was on the other side in big Pharma I can still remember the heated debates we went through prior to the Gleevec launch. They make me smile now, it was quite benign stuff compared to what we could actually do these days.
Imagine you have a new product in development for a particular cancer. You want to educate doctors, patients, health care professionals, the media, analysts etc about the disease and how your drug works, for example. In those days, iv chemotherapy was the rage and there was a certain scepticism that went with trying to develop a pill (a pill?!) for cancer that targeted the leukemia cells and left the normal cells mostly alone. No mention of the product name other than its development code, STI571. Sounds innocuous enough?
The regulatory and legal people made the usual requisite changes from British to American vernacular, nit picked about adding Philadelphia-positive with the CML everywhere etc. Clarified and toned down a few descriptions, which made them longer (not for Twitter, thats for sure). Fair enough, all acceptable suggestions and easy to execute. But the poor regulatory lady was slowing turning puce and finally could stand it no longer and snapped, accusing me of making claims, of promoting the agent off label etc etc. Finally, when she ran out of steam, I waited and politely pointed out that no off-label claims could be made as the drug wasnt available commercially and no generic name was even mentioned. And so it went on. Eventually, common sense prevailed and the scientific brochures got printed and the molecular biology stuff on the website went up along with similar information on other compounds in development. Theres always safety in numbers, we reasoned.
Now, fast forward 9 years.
Today, that world would be very different. Instead of a static 2D web page with bland, anodyne medical and scientific information, suppose we look at several new tools that are available? A medical information specialist could bookmark key research and scientific papers pertaining to the disease and peer-reviewed publications in Del.icio.us or Google Reader, example. The RSS feed could then be shared on the products webpage and provide a useful source of technical information that would be in the readers interest should they need educational information. A YouTube video could be done showing the novel mechanism of action etc.
What would happen if an enlightened medical, new product or marketing team took the same RSS links and fed them into Twitterfeed and hence to a Twitter or Friendfeed account and aggregated numerous sources of interesting data? Would that be education or promotion? Or suppose there was also a blog with lovely widgets and chicklets saying Add Me to your RSS Reader or Email Me when a new post goes up or Share This with others via StumbleUpon, Digg, Mixx, Facebook etc.
But hang on a minute...
Would that be all covered under DTC or PhRMA guidelines? That tends to only cover television and newpaper ads, for example. If its a drug in development, FDAMA guidelines wouldnt apply. How would DDMAC view things?
Suddenly, youre back in that tricky grey area I found myself in with no safety net and no rules to guide anyone either. The Pharma industry is one of the most highly regulated industries and rightly so where peoples health is concerned. But FDA, OIG and DDMAC also need to change with the times and provide better, clearer and more comprehensive guidelines we can all work with.
Instead, I can see clash between the review team having kittens and an aggressive, bold marketer or commercialisation person with a pipe dream to provide cutting edge information that differentiates them from the competition, just as I was trying to do by pushing the window while staying within the outer boundaries. Paralysis and intense debate ensue. Same situation, same goals, same medium, but very different (and better) tools.
The irresistible force and the immovable object collide. Again.
Plus ça chânge, plus de la même chose.
Whats your view on social media and pharma.

Similar posts: colorectal cancer

The significance of nine can mean many things. Some cats are said to have nine lives. Nine years is more than many marriages last. There are nine innings in baseball. Nine months can bring forth new life. Nine years can mark the change from a toddler to a teenager or can be the defining times that bring a teenager to adulthood. Cloud 9 denotes great happiness. The number nine holds a special meaning for me this year as it marks nine anniversaries since I heard the words you have incurable colon cancer. Nine years of new seasons, birthdays, anniversaries, memories, miracles and hope.
In years past, Ive described this diagnosis as a battle, a fight, a war, a roller-coaster ride, a merry go round, a voyage, a journey, a seven year itch, and even a dance. All fit, but the greatest gift this year has given me is the realization that Im not dying from colon cancer. I am living fully in spite of it. I have reaped the benefits of research, a dedicated team of doctors, and increasing options. In my arsenal has been 5fu, levamisole, leucovorin, irinotecan, oxaliplatin, xeloda, three clinical trials, numerous surgeries, Sir-spheres, Gamma Knife radiation, intrathecal chemotherapy, external beam radiation, and vertebroplasty. None of these, other than 5fu, existed when I was diagnosed. It is important that the momentum continue and that research is not thwarted, not only for me and my family but for the families of 1500 others that will lose loved ones today and each day after today.
Treatment keeps life exciting. I respond well and it has become my time for socialization. I honestly cant imagine my life without it anymore.perhaps that dependency has helped foster my survival. In between treatment, not a moment is wasted! Ive done things that I would have never attempted without cancer (including sky diving and scuba diving)- lobbying with C3: Colorectal Cancer Coalition and on behalf of SIR-spheres, speaking, meeting new people and telling a very private story in extremely public places. My life has touched others as they have touched mine and increased my understanding of hope. Hope is a guiding force in life and is the closest thing to a magic wand. It is the golden gossamer thread that harvests happiness, opens possibilities, promises a future, and encourages getting lost in the moment. With hope, I glimpse the all of life and the within every waking minute. For nine years I have lived with a gift that many never have the opportunity to open. It is the gift of NOW. My children have nine years of journals and thoughts for every step of their youth, pictures and love, memories and moments, and an awareness that not many their age experience. My husband and I have learned to embrace every day and we have a strong appreciation for the present day.
Nine signifies the number of borrowed years that I have enjoyed. On this day nine years ago I was handed a death sentence.one that we are each handed the minute we are bornbut never fully understand. Cancer provides that clarity. It was never expected that I would see the dawn of the new year, my children grow up, another anniversary with my husband, and definitely not my 40th birthday. Much has happened in these past nine years. Every day is a blessing. Nine is incredibly fine.

Similar posts: colorectal cancer

Online brokers take an important role to play when you open an online trading account. Every broker can offer different services and features. You primary research all the online brokers to find the optimum broker to meet your needs. I have listed a large number of online brokers and placed their information for you to read in one easy-to-read webpage. This is a free, "no-cost to you" service for our valued reviewers and can be found on this link: Best Online Brokers or you can email support@cfdfxreport.com

What to search for in an online broker.

Brokerage House rates - this is the range at which you are charged for buying or selling through your online account. These rates are usually charged based on a sliding scale. The more units you purchase in a single transaction, the less the "cost per unit" you will pay. The correct sliding scale can vary and may sometimes be negotiable for larger buys. Compare for each one broker and read the fine print within contracts. Selection the one that best meets your buying and selling style.

History fees - Look for sealed fees in account contracts within the terms and conditions. I of one broker who requires an extra $10 to transfer money out of an account "quickly" as against withdrawing money normally. Hardly a fairly fee, I'd say. All fees should be listed in the terms and conditions listed in opening an account.

Phone access - Online services can go down during hours of service. Gaps to broadband services, power outages and computer problems can stop you from accessing information you need at critical points. This is why you must experience phone access to your online broker. Do not even consider using an online broker if they do not provide phone access.

Access to your money - I prefer giving instant access to my money regular though it is held in a cash account by the broker. Most brokers will experience a cash account facility that is linked to your trading account. My account is linked to a MasterCard account, which means I can access that money anytime through any ATM or make purchases as I would normally using a MasterCard. Don't be misled into thinking you must only have a separate cash holding account with the online broker. There are lots of options open to you as a client and good online brokers will provide several options for your cash holding account.

Additional benefits - seek out those brokers that give you extra motivators to open an account with them. Some offer a limited free brokerage period. Others will offer free reports on the markets you are interested in. These bonus offerings can help you getting you account established and setup a profitable trading account. For more information on finding the best online stock broker feel free to visit our website.

The CFD FX REPORT is the real time traders tool, that gives you daily trading ideas, stock market and forex education.

Similar posts: colorectal cancer

Women in marriages that have problems who are diagnosed with breast cancer have a harder time recovering from the disease.
This fact comes following a U.S. study that found that women in troubled marriages were at increased levels of stress, were less likely to exercise, and had more symptoms associated with their disease.
Women who reported good marriages, tended to exercise when they were supposed too, and overall appeared to recover better from their disease.
The study featured 100 women, 72 of whom reported being in a good marriage.
At the beginning of the study, all women had similar levels of stress.
The quality of the marital relationship may not be the first thing women worry about when they get a cancer diagnosis. But it may have a significant impact on how they cope physically and emotionally, study co-author Hae-Chung Yang, a research associate in psychology at Ohio State University, said in a university news release. Our results suggest that the increases in stress and other problems that come with a distressed marital relationship can have real health consequences and lead to poorer recovery from cancer.

Similar posts: colorectal cancer